Aetna’s legal department remains busy. Days after the company settled out of court with a patient who sued for coverage denial in California, it’s in the news in Florida for much the same reason—but with a bigger claimant.

Researchers have developed a deep learning model for detecting and delineating chronic myocardial infarction (MI), sharing their findings in a new study published by Radiology.

Options are increasing for healthcare consumers looking to check their symptoms with an AI digital platform for self-diagnosis. However, research into the use, accuracy and regulation of these technologies is woefully scant.

A pilot that aims to study the use of blockchain-enabled data technology to track and verify specialty prescription drugs has been approved by the FDA.

The American Society for Radiation Oncology (ASTRO) and the American Urological Association (AUA) have updated their clinical guidelines for adjuvant and salvage radiotherapy following prostatectomy.

Nearly one in six young women who suffer a heart attack can’t be classified under the Fourth Universal Definition of MI, according to a study out of Yale University—but the majority can be accurately classified using a sex-specific taxonomy known as VIRGO.

Prostatic artery embolization (PAE) is an effective, minimally invasive treatment option for men with enlarged prostates, according to a new position statement from four interventional radiology societies.

A little less than half of atherosclerotic cardiovascular disease (ASCVD) patients are treated for blood cholesterol according to 2013 clinical guidelines, with around half missing out on a statin prescription the guidelines would have recommended, according to a study published in the American Journal of Cardiology.

Johns Hopkin’s researchers have created a PET-based approach that can direct cancer drugs to precise points in the brains of mice, according to a study published in the May 1 edition of the Journal of Nuclear Medicine. If proven effective in humans, the researchers believe their technique could help patients with difficult brain tumors, such as glioblastomas.

CVS Health, fresh off a $69 billion takeover of health insurance giant Aetna, saw its revenues increase 34.8% to $61.6 billion during the first quarter of 2019, according to a May 1st earnings report. In addition, net income rose 43%, to $1.4 billion, from the previous year.